Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale‐up of direct‐acting antiviral treatment

The recent downward revision of the estimated number of people living with chronic hepatitis C in Australia means that the annual number of new hepatitis C infections should also be revised. We aimed to estimate the annual number of new hepatitis C infections among people who inject drugs (PWID) in Australia in 2015, prior to the introduction of direct‐acting antiviral (DAA) treatment for hepatitis C, as an updated baseline measure for assessing the impact of DAAs on hepatitis C incidence over the next 10 years.

• Publication year

  2021

• Venue

  Journal of Gastroenterology and Hepatology

• Publication date

  2021-03-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jgh.15485PMID 33691343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.

  2019cited by this paper
• Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016.

  2019cited by this paper
• The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals

  2019cited by this paper
• Estimating the number of people who inject drugs in Australia

  2017cited by this paper
• Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta‐analysis

  2017cited by this paper
• HIV, viral hepatitis and sexually transmissible infections in Australia

  2016cited by this paper
• The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs

  2016cited by this paper
• Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis

  2016cited by this paper
• Surveillance of injecting‐related injury and diseases in people who inject drugs attending a targeted primary health care facility in Sydney's Kings Cross

  2015cited by this paper
• Healthcare seeking behaviour among self-help group households in Rural Bihar and Uttar Pradesh, India

  2015cited by this paper
• Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS‐c study

  2014cited by this paper
• High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study

  2013cited by this paper
• Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study.

  2013cited by this paper
• Identifying newly acquired cases of hepatitis C using surveillance: a literature review

  2012cited by this paper
• Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection.

  2010cited by this paper
• Communicable diseases surveillance.

  2008cited by this paper
• Modelling the hepatitis C virus epidemic in Australia.

  2007cited by this paper
• Substance Abuse Treatment, Prevention, and Policy BioMed Central Commentary The "lessons " of the Australian "heroin shortage"

  2006cited by this paper
• Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

  2003cited by this paper
• History and current status of the National Notifiable Diseases Surveillance System.

  1996cited by this paper

• Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020.

  2022cites this paper
• Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.

  2022cites this paper
• Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study

  2021cites this paper